Zydus Lifesciences Limited has informed the Exchange regarding a revised press release dated August 24, 2023, titled "Zydus receives final approval from the USFDA for Zinc Sulfate Injection USP, 10 mg/10 mL (1 mg/mL), 30 mg/10 mL (3 mg/mL), and 25 mg/5 mL (5 mg/mL) Pharmacy Bulk Package Vials".
Press Release (Revised) Aug 24 2023
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a revised press release announcing final approval from the USFDA for Zinc Sulfate Injection Pharmacy Bulk Package Vials. The approval covers multiple formulations of the injection, which is used for parenteral nutrition when oral intake is not feasible. The drug will be manufactured at Zydus's facility in Jarod, and it had significant annual sales in the United States.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Aug 24 2023
- Press Release Aug 17 2023
- Press Release Aug 11 2023
- Press Release Aug 03 2023
- Press Release Jul 27 2023
Later from Zydus Lifesciences
- Press Release Aug 25 2023
- Press Release Aug 31 2023
- Press Release Sep 01 2023
- Press Release Sep 13 2023
- Press Release Sep 15 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences